Inactive Instrument

Spark Therapeutics, Inc.

US84652J1034

Biotechnology & Medical Research

Spark Therapeutics, Inc. has completed an IPO in the amount of $161.00 million.

January 29, 2015 at 10:30 am IST

Spark Therapeutics, Inc. has completed an IPO in the amount of $161.00 million.

Offer Details:
Security Type: Common Stock
Offered: 7000000
Price/Range: 23.00

Latest news about Spark Therapeutics, Inc.

CombiGene Enters into A License Agreement with Spark for the Epilepsy Project CG01	24/06	CI
Senti Biosciences, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	13/05	CI
Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	15/23/15	CI
Spark Therapeutics, Inc. Enters into Strategic Collaboration with Neurochase Limited for Use of Proprietary Delivery Technology for CNS Disorders	27/23/27	CI
Spark Therapeutics, Inc. Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A	12/22/12	CI
Spark Therapeutics, Inc. Announces Executive Changes, Effective April 1, 2022	23/22/23	CI
Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe	16/21/16	CI
Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII Expression that Significantly Reduced Bleeding in Hemophilia A Patients	18/21/18	CI
CombiGene in Billion-Dollar Deal with Spark Therapeutics	12/21/12	CI
NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease	07/21/07	CI
Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date	21/21/21	CI
Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform	13/21/13	CI
Spark Therapeutics Appoints Cynthia Pussinen as Chief Technical Officer	25/21/25	CI
Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress	05/21/05	CI
Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease	01/21/01	CI
Spark Therapeutics Appoints Michael Retterath as Chief Strategy Officer	16/20/16	CI
Spark Therapeutics, Inc. Appoints Gallia Levy as Chief Medical Officer	10/20/10	CI
Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress	12/20/12	CI
Spark Therapeutics, Inc. Demonstrates Role of Ides in Enabling of Gene Therapy in the Presence of Neutralizing Anti-Aav Antibodies Published in Nature Medicine	01/20/01	CI
Spark Therapeutics, Inc.(NasdaqGM:ONCE) dropped from S&P TMI Index	23/19/23	CI
Spark Therapeutics, Inc.(NasdaqGM:ONCE) dropped from S&P Global BMI Index	23/19/23	CI
Spark Therapeutics, Inc.(NasdaqGM:ONCE) dropped from S&P Biotechnology Select Industry Index	23/19/23	CI
Trouble for Boeing, Netflix expands, Amazon toughens up against Fedex…	17/19/17
Spark Therapeutics, Inc. Announces Board Changes	17/19/17	CI
Spark Therapeutics : Roche to complete $4.3 billion Spark deal as regulators give all clear	17/19/17	RE

Chart Spark Therapeutics, Inc.

Duration

Period

More charts

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+22.77%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-14.06%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B

Bio Therapeutic Drugs